These results indicate that, like shRNA-mediated silencing of PHD3 in PDA cells, natural silencing of PHD3 in pancreatic cancer also appears to be associated with a mesenchymal-like phenotype at the level of gene expression. Here, EGLN3 is linked to Patent ductus arteriosus.